Nalaganje...
Combination of Bevacizumab, Irinotecan and Temozolomide for Refractory or Relapsed Neuroblastoma: Results of a Phase II Study
BACKGROUND: The rationale for studying the combination of bevacizumab, irinotecan and temozolomide (BIT) in neuroblastoma is based on: (a) vascular endothelial growth factor (VEGF) expression is associated with an aggressive phenotype, (b) anti-VEGF antibody bevacizumab enhances irinotecan-mediated...
Shranjeno v:
| izdano v: | Pediatr Blood Cancer |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5555116/ https://ncbi.nlm.nih.gov/pubmed/28111925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26448 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|